CFN
CORT icon

Cordasco Financial Network’s Corcept Therapeutics CORT Stock Holding History

Cordasco Financial Network’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-185
Closed -$2K – 466
2019
Q1 		$2K Buy
+185
New +$2.3K ﹤0.01% 418

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Cordasco Financial Network's CORT Position: Q2 2019 in Review

Cordasco Financial Network sold out of Corcept Therapeutics (CORT) in Q2 2019, closing a stake of 185 shares — an estimated $2K sold.

Cordasco Financial Network first reported a position in CORT in Q1 2019 and held it in 1 quarter. The position peaked at $2K in Q1 2019. 183 funds tracked by Wall St. Rank hold CORT as of Q2 2019.

  • Cordasco Financial Network reported no remaining Corcept Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Cordasco Financial Network sold 185 Corcept Therapeutics shares in Q2 2019, an estimated $2K.
  • Cordasco Financial Network first reported a position in Corcept Therapeutics in Q1 2019 and held it in 1 quarter.
  • Cordasco Financial Network's Corcept Therapeutics position peaked at $2K in Q1 2019.
  • 183 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2019.

Based on Cordasco Financial Network's 13F filing for Q2 2019, filed 10 Jul 2019.